Publications

Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD

Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.

Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the icatibant outcome survey

Filename 263. Longhurst et al, IOS comparing HAE Type II-II,CEI 2017.pdf
Filesize 242.67 KB
Version o.263
Date added July 30, 2020
Downloaded 0 times
Category Original Work
Tags acquired angioedema, Hereditary Angioedema, Icatibant
Authors Longhurst, H. J., Zanichelli, A., Caballero, T., Bouillet, L., Aberer, W., Maurer, M. Fain, O., Fabien, V., and Andresen, I.
Citation Longhurst, H. J., Zanichelli, A., Caballero, T., Bouillet, L., Aberer, W., Maurer, M. Fain, O., Fabien, V., and Andresen, I.: Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the icatibant outcome survey. Clin. Exp. Immunol. 2017: 188; 148-153.
Corresponding authors Longhurst, H. J.
DocNum O.263
DocType PDF
Edition; Page 188; 148-153
IF 3.54
Publisher Clin. Exp. Immunol.
ReleaseDate 2017

Icatibant is used to treat acute hereditary angioedema with C1 inhibitordeficiency types I/II (C1-INH-HAE types I/II) and has shown promise inangioedema due to acquired C1 inhibitor deficiency (C1-INH-AAE). Datafrom the Icatibant Outcome Survey (IOS) were analysed to evaluate theeffectiveness of icatibant in the treatment of patients with C1-INH-AAE andcompare disease characteristics with those with C1-INH-HAE types I/II. Keymedical history (including prior occurrence of attacks) was recorded uponIOS enrolment. Thereafter, data were recorded retrospectively atapproximately 6-month intervals during patient follow-up visits. In theicatibant-treated population, 16 patients with C1-INH-AAE had 287 attacksand 415 patients with C1-INH-HAE types I/II had 2245 attacks. Patientswith C1-INH-AAEversusC1-INH-HAE types I/II were more often male (69versus42%;P50035) and had a significantly later mean (95% confidenceinterval) age of symptom onset [579 (5133–6453)versus140 (1270–1526) years]. Time from symptom onset to diagnosis was significantlyshorter in patients with C1-INH-AAEversusC1-INH-HAE types I/II (mean123 monthsversus1181 months;P50006). Patients with C1-INH-AAEshowed a trend for higher occurrence of attacks involving the face (35versus21% of attacks;P50064). Overall, angioedema attacks were more severe inpatients with C1-INH-HAE types I/IIversusC1-INH-AAE (61versus40% ofattacks were classified as severe to very severe;P<0001). Median totalattack duration was 50hand90 h for patients with C1-INH-AAEversusC1-INH-HAE types I/II, respectively.

 

(Last update: 12.2023)

Number of original publications in peer-reviewed journals:580
Number of reviews in peer-reviewed journals:210
Number of publications (original work and reviews) in peer-reviewed journals:790
Cumulative IF for original publications in peer-reviewed journals:4196.39
Cumulative IF for reviews in peer-reviewed journals:1409.32
Cumulative IF of publications (original work & reviews) in peer-reviewed journals:5605.71
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023)36836

Download-Information

To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.